Advertisement
Document › Details
Lytix Biopharma AS. (8/22/17). "Press Release: Norwegian Cancer Society Invests in Lytix Biopharma AS".
Organisation | Lytix Biopharma AS | |
Organisation 2 | Norwegian Cancer Society | |
Product | LTX-315 (Lytix Biopharma) | |
Product 2 | oncology | |
Index term | Lytix Biopharma–SEVERAL: investment, 201704 private placement NOK60m incl NOK6m from Norwegian Cancer Society | |
Person | Wickholm, Håkan (Lytix Biopharma AS 201603– CEO) | |
Lytix Biopharma is pleased to announce that the Norwegian Cancer Society has invested 6 million NOK in the Company as part of the prior private placement of 60 million NOK.
”We are proud that this competent and important institution has invested in Lytix. This as a further confirmation that our drug development within immune-oncology is on the right track, and we greatly appreciate the value of having the Norwegian Cancer Society in place as a significant investor”, says Håkan Wickholm, CEO of Lytix Biopharma.
“We have followed Lytix Biopharma closely over some years. Their technology within oncolytic peptides has been evaluated thoroughly. LTX-315 is a very interesting drug candidate and we found the time right to invest in Lytix Biopharma. We hope that the future development can bring clinical benefits for our cancer patients”, says Anne Lise Ryel, Secretary General of the Norwegian Cancer Society.
Read related article in Dagens Medisin (only in Norwegian)
Record changed: 2023-06-05 |
Advertisement
More documents for Lytix Biopharma AS
- [1] Lytix Biopharma AS. (9/12/19). "Press Release: Lytix Biopharma AS Appoints Øystein Rekdal as the new CEO"....
- [2] Targovax ASA. (9/13/18). "Press Release: Targovax Strengthens Management Team With the Appointment of Torbjørn Furuseth as CFO; Erik Digman Wiklund to become CBO". Oslo....
- [3] Redx Pharma plc. (1/22/18). "Press Release: Redx Pharma Appoints Chief Medical Officer Who Will Oversee Launch of Phase I Clinical Trial of New Cancer Drug"....
- [4] Lytix Biopharma AS. (8/21/17). "Press Release: Lytix Strengthens the Board with Clinical Development and Commercial Oncology Experience"....
- [5] Lytix Biopharma AS. (4/21/17). "Press Release: Lytix Biopharma Completes 1st Combination Cohort of LTX-315 and Pembrolizumab in TNBC"....
- [6] Lytix Biopharma AS. (4/20/17). "Press Release: Lytix Biopharma Raises in Total 80 Million NOK"....
- [7] Lytix Biopharma AS. (1/13/17). "Press Release: Lytix Biopharma Announces the Appointment of Torbjørn Furuseth as CFO"....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top